AbbVie Gets FDA Approval of Oral Rinvoq to Treats Adults With AS

AbbVie says the FDA has approved RINVOQ as an oral treatment for adults with active ankylosing spondylitis.

• Approval supported by Phase 3 SELECT-AXIS 2 clinical trial and the Phase 2/3 SELECT-AXIS 1 clinical trial
• In both trials, a greater proportion of RINVOQ 15 mg patients achieved the primary endpoint of an ASAS40 response vs placebo

NOTE

• AbbVie Inc. fell 8.6% to $142.85 as of 2:49 p.m. New York time
  • The average 12-month price target of $162.64 is 13.9% above the current price
  • 18 buys, 7 holds, 1 sells

To view the source of this information, click here

To contact the ...